ClinicalTrials.gg
WithdrawnNCT04309734Updated Jun 8, 2022

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

A Phase 1/2 interventional study of AT-777 and Placebo in Hepatitis C, Hepatitis C, Chronic and Chronic Hepatitis C, sponsored by Atea Pharmaceuticals, Inc.. Withdrawn at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-08.

Primary conditionHepatitis C, ChronicRegistry: Hepatitis CReclassifiedWhy we changed it
Registry
Hepatitis C — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis C, Chronic
Why
  1. The study's listed conditions name Hepatitis C, Chronic, a narrower term within Hepatitis C.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Withdrawn prior to study initiation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Hepatitis C, Chronic with a site in Belgium — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Belgium.

Enrollment
38th of 38
0 · median 266
Started
2021
the only one that year
Phase 1/2
Only one
of the 46
Registered
45th of 46
by date
Lead sponsor
3 of 46
Atea Pharmaceuticals, Inc.

Among the 46 studies in Hepatitis C, Chronic with a site in Belgium, this one is the 38th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 1/2, and was the 45th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 46 studies in Hepatitis C, Chronic with a site in Belgium is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies in Hepatitis C, Chronic with a site in Belgium as a file.
02

Study summary

This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.

03

Conditions studied

  • Hepatitis C
  • Hepatitis C, Chronic
  • Chronic Hepatitis C
  • Hepatitis C Virus Infection
  • HCV Infection

Browse trials for

04

In context

Hepatitis C, Chronic Reclassified

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Lead sponsor

Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.

Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis C. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All:

  • (BMI) of 18-35 kg/m2
  • Must agree to use protocol-specified methods of
  • Negative pregnancy test
  • Willing to comply with the study requirements and to provide written

Additional for Part A:

-18-55 years of age

Additional for Part B:

  • 18-65 years of age
  • genotype 1, 2 or 3
  • Documented history compatible with chronic hepatitis C
  • HCV RNA ≥ 10,000 IU/mL at Screening

Exclusion criteria

Exclusion Criteria:

All:

  • Pregnant or breastfeeding
  • Abuse of alcohol or drugs
  • Use of other drugs within 30 days of dosing
  • Other medical conditions

Additional for Part B:

  • Prior exposure to any NS5A inhibitor
  • Cirrhosis
  • Co-infection with virus or
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A - 60 mg AT-777 single dose

    Drug: AT-777

  • Experimental
    Part A - 120 mg AT-777 single dose

    Drug: AT-777

  • Placebo comparator
    Part A - Placebo single dose

    Drug: Placebo

  • Experimental
    Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks

    Drug: AT-777 · Drug: AT-527

Interventions

  • DrugAT-777

    Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.

  • DrugPlacebo

    Administered orally, as one or two placebo capsules, depending on the arm.

  • DrugAT-527

    Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Number of subjects experiencing treatment-emergent adverse events

    Time frame: Through Day 6 for subjects in Part A

  2. Incidence of Treatment-Emergent Adverse Events

    Number of subjects experiencing treatment-emergent adverse events

    Time frame: Through 4 weeks after end of treatment for subjects in Part B

  3. Antiviral Activity of AT-777 and AT-527

    Number of subjects who achieve plasma HCV RNA \< lower limit of quantitation (LLOQ) and target not detected (TND)

    Time frame: Through 2 weeks of treatment for subjects in Part B

Secondary outcomes

  1. AT-777 maximum plasma concentration (Cmax)

    PK

    Time frame: Day 1 for subjects in Part A

  2. AT-777 area under the concentration-time curve (AUC)

    PK

    Time frame: Day 1 for subjects in Part A

  3. Proportion of subjects achieving sustained virologic response (SVR)

    SVR defined as the HCV RNA \< lower limit of quantitation (LLOQ) at 12 weeks after end of treatment

    Time frame: 12 weeks after end of treatment for subjects in Part B

08

Study locations

1 site
  • Clinical Trial Site
    Antwerp, Belgium
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Jun 2022, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2020
First posted
Mar 16, 2020
StartEst.
Oct 2021
Primary completionEst.
Jun 2022
CompletionEst.
Sep 2022
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04309734
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Oct 2021 (estimated)
Primary completion
Jun 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Jun 8, 2022

Study contacts

Xiao-Jian Zhou
study director · Atea Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion